Clinical trials: Mask
Presbyopia
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.
- Trial name
- NCT05124275
- Testing
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3
- Where
- 10 sites in United States
- Volunteers
- 123 people
- Sponsor
- Glaukos Corporation
Macular Edema, Diabetic Mellitus
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.
- Conditions
- Macular Edema, Diabetic Mellitus, Retinal Disease
- Trial name
- NCT01100307
- Testing
- pegaptanib sodium
- Where
- 43 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Pfizer
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Healthy Volunteers
A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
This study is a multicenter, randomized, double-masked, parallel-group, reference-drug-controlled clinical trial of IBI3027 in healthy male volunteers.
- Trial name
- NCT07502534
- Testing
- IBI3027, DUPIXENT® (dupilumab)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Ocular Hypertension, Open Angle Glaucoma
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT07082816
- Testing
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
- Where
- 30 sites in United States
- Volunteers
- 489 people
- Sponsor
- Alcon Research
Primary Vitreoretinal Lymphoma
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary…
- Trial name
- NCT07402876
- Testing
- ICM ADX-2191 injection, Monthly ADX-2191 injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cataract Senile
Extended Depth of Focus (EDF) Intraocular Lens (IOL) Versus Monofocal Intracoular Lens (IOL)
Extended depth of focus (EDF) intraocular lens (IOL) versus Monofocal intraocular lens (IOL)
- Trial name
- NCT07092020
- Testing
- EDF, Monofocal IOL
- Where
- 14 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 220 people
- Sponsor
- Carl Zeiss Meditec AG
Macular Degeneration, Geographic Atrophy
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).
- Trial name
- NCT03815825
- Testing
- IONIS-FB-LRx
- Where
- 88 sites in United States, Australia and 7 more
- Volunteers
- 332 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Presbyopia
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
Presbyopia is a condition in which the eye exhibits a diminished ability to focus on near objects with increasing age. This study will assess the safety and exploratory efficacy of AGN-190584 is in treating participants with…
- Trial name
- ARIES (NCT05393089)
- Testing
- AGN-190584, Vehicle
- Where
- 32 sites in United States
- Sponsor
- Allergan
Choroidal Neovascularization, Age-related Macular Degeneration
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared…
- Trial name
- EMERGE (NCT02358889)
- Testing
- hI-con1, ranibizumab
- Where
- 48 sites in United States
- Volunteers
- 88 people
- Sponsor
- Iconic Therapeutics, Inc.
Eye Infections, Postoperative Complications
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
The purpose of this study is to demonstrate the bioequivalence of the combination test agent, prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension compared to PredForte (prednisolone acetate 1.0%) ophthalmic…
- Trial name
- NCT00198523
- Testing
- Prednisolone and Tobramycin, Prednisolone
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Bausch & Lomb Incorporated
Age Related Cataracts
The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract
The study objectives were: To evaluate the efficacy of EDTA 1.3% and 2.6% ophthalmic solution (C-KAD) in improving visual function as assessed by contrast sensitivity; To evaluate the safety and tolerability of two doses of EDTA…
- Trial name
- NCT06365762
- Testing
- EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%
- Where
- 6 sites in United States
- Volunteers
- 111 people
- Sponsor
- Livionex Inc.
Dry Eye Syndrome, Tear Film Insufficiency
Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye
The objective of the clinical investigation was to evaluate tolerability, safety and efficacy of the tested medical device, eye drop containing Lubricin 150 µg/mL, as compared with a standard sodium hyaluronate 0.13% eye drop…
- Trial name
- NCT02510235
- Testing
- Lubricin, Sodium Hyaluronate
- Where
- 2 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Obstructive Sleep Apnea
PAP Systems Internal Clinical Studies (ICS)
This is a pre-market study for ongoing product development aiming to explore the usability and performance of the study PAP systems to guide product development.
- Trial name
- NCT06173050
- Testing
- PAP System A (with Amalfi) then PAP System B (with CLA11), PAP System B (with CLA11) then PAP System A (with Amalfi)
- Where
- Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ResMed
Corneal Transplantation
Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery
Compare the corneal penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing penetrating keratoplasty (PK)
- Trial name
- NCT00764582
- Testing
- 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Central Serous Chorioretinopathy
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
This is a prospective, multicentre, sham-controlled, participant- and assessor-masked superiority trial with two parallel treatment arms which aims to investigate the safety and efficacy of subthreshold nanosecond laser (SNL) in…
- Trial name
- NANO-C (NCT05570591)
- Testing
- 2RT subthreshold nanosecond laser - active
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Nova Eye Medical Pty Ltd.
Age-Related Macular Degeneration
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab.
- Trial name
- NCT00607750
- Testing
- ATG003 (mecamylamine)
- Volunteers
- 60 people
- Sponsor
- CoMentis
Dry Eye
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
The objectives of this study are to compare the efficacy and safety of tanfanercept ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.
- Trial name
- VELOS-4 (NCT06400589)
- Testing
- tanfanercept, Vehicle
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- HanAll BioPharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.